NCT03463473 is a Phase 1 clinical trial of 3 mg/kg Q3W MSB2311 Injection in Advanced Solid Tumors, sponsored by Suzhou Transcenta Therapeutics Co., Ltd..

Who is sponsoring NCT03463473?

NCT03463473 is sponsored by Suzhou Transcenta Therapeutics Co., Ltd..

What drugs are being tested in NCT03463473?

Interventions in NCT03463473: 3 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q3W MSB2311 Injection, 20 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q2W MSB2311 Injection.

What condition does NCT03463473 study?

NCT03463473 studies Advanced Solid Tumors.

Is NCT03463473 still recruiting?

NCT03463473 is currently completed. Last updated 18 December 2023.

Last reviewed 2023-12-18 · How we verify

NCT03463473

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of MSB2311 in Advanced Solid Tumors

Completed Phase 1 Last updated 18 December 2023

What this trial tests

Phase 1 trial testing 3 mg/kg Q3W MSB2311 Injection in Advanced Solid Tumors in 42 participants. Completed in 1 June 2020.

Timeline

12 April 2018

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	Suzhou Transcenta Therapeutics Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	12 April 2018
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	1 location across United States

Drugs / interventions tested

3 mg/kg Q3W MSB2311 Injection — full drug profile →
10 mg/kg Q3W MSB2311 Injection — full drug profile →
20 mg/kg Q3W MSB2311 Injection — full drug profile →
10 mg/kg Q2W MSB2311 Injection — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Suzhou Transcenta Therapeutics Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C, Liu Y. · · 2020 · cited 75× · PMID 32714324 · DOI 10.3389/fimmu.2020.01295
Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
Manso T, Kushwaha A, Abdollahi N, Duroux P, et al · · 2023 · cited 21× · PMID 37215135 · DOI 10.3389/fimmu.2023.1129323
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q, Zhang J, Zhong H, Yuan Y, et al · · 2023 · cited 1× · PMID 37115210 · DOI 10.1007/s00262-023-03434-2

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Suzhou Transcenta Therapeutics Co., Ltd. trials

Trials by the same sponsor.

NCT06093425 — Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GE · Phase 3 · not yet recruiting
NCT04958434 — Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors · Phase 1 · terminated
NCT04495296 — A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic · Phase 1, PHASE2 · recruiting
NCT04396821 — A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · active not recruiting
NCT04381325 — A Study of MSB0254 Injection in Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03463473 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suzhou Transcenta Therapeutics Co., Ltd.
Last refreshed: 18 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03463473.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing